help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhami, R.
Right arrow Articles by Churg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhami, R.
Right arrow Articles by Churg, A.
Am. J. Respir. Cell Mol. Biol., Volume 22, Number 2, February 2000 244-252

Acute Cigarette Smoke-Induced Connective Tissue Breakdown Is Mediated by Neutrophils and Prevented by alpha 1-Antitrypsin

Rajwinder Dhami, Blake Gilks, Changshi Xie, Katalin Zay, Joanne L. Wright, and Andrew Churg

Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada


    Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Recent studies have suggested that macrophage-derived metalloproteases are the critical mediators of cigarette smoke-induced emphysema, in contrast to earlier hypotheses that this process was mediated by neutrophil elastase. To determine whether smoke can acutely induce connective tissue breakdown in the lung and to examine the mediators of this process, we exposed C57-BL/6 mice to whole cigarette smoke and used high-performance liquid chromatography to examine lavage fluid levels of desmosine (DES), a marker of elastin breakdown, and hydroxyproline (HP), a marker of collagen breakdown. Smoke produced a dose-response increase in lavage neutrophils, DES, and HP, but not lavage macrophages (MACs). This effect was evident by 6 h after exposure to two cigarettes. Pretreatment with an antibody against polymorphonuclear leukocytes (PMNs) reduced lavage PMNs to undetectable levels after smoke exposure, did not affect MAC numbers, and prevented increases in lavage DES and HP. Intraperitoneal injection of a commercial human alpha 1-antitrypsin (alpha 1AT) 24 h before smoke exposure increased serum alpha 1AT levels approximately 3-fold and completely abolished smoke-induced connective tissue breakdown as well as the increase in lavage PMNs, again without affecting MAC numbers. We conclude that in this model cigarette smoke can acutely induce connective tissue breakdown and that this effect is mediated by neutrophil-derived serine proteases, most likely neutrophil elastase. Exogenous alpha 1AT is protective and appears to inhibit both matrix degradation and PMN influx, suggesting that alpha 1AT has anti-inflammatory as well as antiproteolytic effects in this system.


    Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Emphysema is characterized by abnormal irreversible enlargement of the air spaces in the lung resulting from progressive degradation of the extracellular matrix of the alveolar walls (1, 2). Evidence acquired over the past 30 years has led to the idea that matrix degradation results from an excess of inflammatory cell-derived proteolytic activity and a relative paucity of antiproteolytic defense in the lower respiratory tract, a theory often referred to as the protease-antiprotease hypothesis. In cigarette smokers, the traditional theory states that the effector cell is the neutrophil (polymorphonuclear leukocyte [PMN]), the crucial protease neutrophil elastase, and that cigarette smoke also inactivates alpha 1-antitrypsin (alpha 1AT), the major antiproteolytic substance in the lung parenchyma.

In patients with hereditary alpha 1AT deficiency, this fundamental scenario appears to be correct, and some reports suggest that progression of emphysema may be ameliorated by administration of alpha 1AT (3, 4). However, in cigarette smokers the issue of what cell, what protease(s), and what antiproteolytic substances are involved has become increasingly controversial. Attempts to show that alpha 1AT levels in smokers are different from those in nonsmokers, or that the alpha 1AT present has reduced function, have led to contradictory results: some studies show lower levels of alpha 1AT, or a decreased association rate between alpha 1AT and neutrophil elastase, or the presence of oxidized methionine residues in the protein leading to a loss of inhibitory function; whereas an equal number of studies have shown that alpha 1AT levels in smokers are the same as those in nonsmokers and that there is no evidence of oxidative inactivation or other loss of function (reviewed in 2, 5).

The idea that the PMN is the effector cell has become equally controversial. Cigarette smoke causes an increase in both lavage and tissue PMNs and macrophages (MACs) (8). Although increased numbers of PMNs can be detected in the alveolar walls in smokers, and experimental instillation of neutrophil elastase produces emphysema in laboratory animals (10), the numbers of PMNs present in human tissue do not correlate with the degree of lung destruction, whereas correlations are obtained with numbers of MACs (9, 12). The traditional view that MAC proteases show little elastolytic activity compared with neutrophil elastase has been modified by the recognition that a variety of MAC-derived metalloproteases, including gelatinase A and B, matrilysin, and MAC metalloelastase, all can degrade elastin (13). It has also become apparent from human and experimental studies that emphysema is characterized not only by breakdown of elastin but also by breakdown and resynthesis of collagen with scar formation (2, 5, 16, 17).

These observations have led to an alternate formulation of the protease-antiprotease hypothesis in which MACs are the crucial cells and MAC-derived proteases, particularly metalloproteases, are the effector agents (14, 18). Sansores and colleagues (19) found that air space and interstitial MACs from smoke-exposed guinea pigs showed increased elastolytic activity, and Finlay and associates (20) reported similar observations using cultured MACs derived from human lavage fluid. Selman and colleagues (21) showed upregulation of interstitial collagenase in smoke-exposed guinea pigs, and D'Armiento and coworkers (22) showed that transgenic mice overexpressing interstitial collagenase developed emphysema. Hautamaki and associates (18) created mice in which the gene for MAC metalloelastase had been knocked out and observed that these mice did not develop emphysema when exposed to cigarette smoke. Ohnishi and coworkers (23) found increased levels of various metalloproteases including matrix metalloproteinase (MMP)-1, MMP-2, MMP-8, and MMP-9 in human lungs with emphysema compared with lungs without. More recently, Ofulue and associates (24) reported that the development of emphysema in smoke-exposed guinea pigs correlated with MAC but not PMN numbers and MAC-derived proteolytic activity, and that depletion of MACs prevented smoke-induced emphysema whereas depletion of PMNs was not protective (25).

All of these studies continue to raise questions about the cells and proteases involved in smoke-induced connective tissue breakdown in the lung, the process that ultimately leads to emphysema, as well as the time course of these events. In this study we have used a very acute smoke-injury model to examine connective tissue breakdown and to determine which cells and proteases (or groups of proteases) are involved.

    Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Smoke Exposure and Lavage Procedures

Each experimental group consisted of five C57-BL/6 mice. Mice were exposed to the whole smoke from two full Kentucky 2R1 cigarettes (obtained from the University of Kentucky) using a standard smoking apparatus (described by us elsewhere [26]). Control mice were sham-smoked. At various times following smoke exposure, mice were killed by halothane overdose, and the lungs were removed from the chest cavity. A 20-gauge catheter was inserted into the trachea and the lungs were lavaged six times with 1 ml of ice-cold saline for cell counts or with distilled water for connective tissue degradation analysis (water was used because concentration of salts during sample preparation for the high-performance liquid chromatography [HPLC] procedure interferes with the analysis of desmosine [DES] [27]).

For inflammatory cell measurements, the saline lavage was centrifuged at 200 × g at 4°C for 10 min. The supernatants were decanted and the cell pellets were resuspended in 200 µl of saline. Total cell counts were performed in a hemacytometer and differential cell counts were performed on a 10-µl drop of the cell suspension heat-fixed on a slide and stained with hematoxylin and eosin.

To examine the effects of a single smoke exposure over time, C57-BL/6 mice were exposed to smoke from two whole cigarettes; test and control groups were killed 6, 24, and 48 h after smoke exposure, and their lungs were lavaged. To examine the effects of cigarette smoke dose, groups of mice were exposed to one, two, or three whole cigarettes and killed 24 h later.

alpha 1AT Purification, Administration, and Serum Levels

Purified human alpha 1AT (Prolastin) was purchased from Bayer, Inc. (Etobicoke, ON, Canada) and the preparation was further purified to remove contaminating proteins. Prolastin was reconstituted in 20 mM sodium phosphate buffer (pH 7.6) and filtered through an Ultra-Free 15 100K centrifugal filter device (Millipore, Bedford, MA) to remove proteins of 100-kD size or greater. The concentrate was washed several times with buffer and the resulting filtrates were pooled. The pooled filtrate was run through a Cibacron Blue column (Pharmacia, Oakville, ON, Canada) at 4°C to selectively remove albumin, the major contaminating protein. Human alpha 1AT was washed out of the column with sodium phosphate buffer (pH 7.6). Finally, the solution was concentrated with an Amicon ultrafiltration cell using a 10K Diaflo membrane (Amicon, Beverly, OK). Purity of the resulting product was checked on a 12.5% homogenous Phastgel (Pharmacia) with silver staining.

Initial experiments were performed to determine the increase in serum alpha 1AT after injection of various amounts of purified product and to determine the time course of the serum elevation (see RESULTS) after intraperitoneal injection. For this purpose blood was drawn from the tail vein and analyzed by a competitive enzyme-linked immunosorbent assay (ELISA) using purified human alpha 1AT as a standard (Calbiochem, La Jolla, CA). The plates were coated with 100 ng/well alpha 1AT and blocked with phosphate-buffered saline (PBS) containing 3% bovine serum albumin at pH 7.4. A total of 50 µl of sample was added into the wells, followed by 50 µl of antihuman alpha 1AT antibody (Boehringer Mannheim, Laval, PQ, Canada) depleted against mouse serum. After the solution was mixed, the plate was incubated for 1 h at room temperature. After incubation the plate was washed five times with PBS. A total of 100 µl of secondary antibody (goat antirabbit immunoglobulin G-horseradish peroxidase [HRP] 1:10,000) was measured into each well. After 1 h incubation at room temperature, the plate was washed five times with PBS. The color reaction was developed using TMB ELISA substrate (ICN Biochemicals). A total of 100 µl of substrate was added into each well and incubated for 5 min. Color development was stopped by the addition of 100 µl 2 M HCl solution. Absorbance was measured at 450 nm.

After examination of the data, a dose of 20 mg of purified product in 1.0 ml of saline was selected and mice were injected 24 h before smoke exposure.

Western Blot Analysis of Bronchoalveolar Lavage Fluid for alpha 1AT

Unconcentrated bronchoalveolar lavage (BAL) fluid (BALF) samples were separated on a 12% polyacrylamide resolving gel with purified human alpha 1AT (Sigma, Mississauga, ON, Canada) as a positive control. After electrophoresis, the protein bands were immobilized on a nitrocellulose membrane and the membrane was probed with antihuman alpha 1AT primary antibody (Boehringer Mannheim) and goat antirabbit HRP-conjugated antibody (ICN Biochemicals) and developed by enhanced chemiluminescence (Amersham, Oakville, ON, Canada).

Depletion of Neutrophils

Neutrophils were depleted by administration of an antimouse neutrophil antibody (APA, Cat. no. AIA31140; Accurate Scientific, Westbury, NY). Two intraperitoneal injections of 0.2 ml of antibody were given 24 h apart. Test lavages and blood counts 24 h after intratracheal instillation of 50 µg of lipopolysaccharide (LPS) (used here as an agent known to evoke a marked lavage neutrophilia), administered 24 h after the second antibody dose, showed that this procedure succeeded in depleting 100% of the PMNs from the peripheral blood and more than 90% of the PMNs in the lavage. For smoke experiments, mice were exposed to smoke or air 24 h after the second antibody dose.

DES and Hydroxyproline Analysis

The water lavageate was lyophilized and hydrolyzed in HCl at 110°C for 48 h, and then analyzed for DES and hydroxyproline (HP) on a Waters HPLC system (Waters Associates, Milford, MA) using our previously published protocol (26).

BALF Elastase-Like Activity

Elastase-like activity in BALF was measured by colorimetric assay. BALF samples were lyophilized and reconstituted in water to make a solution that was five times more concentrated than the originial sample. N-succinyl-Ala-Ala-Ala-p-nitroanilide (SLAPN; Sigma) was used as the substrate. The assay was carried out in 0.2 M Tris-HCl, pH 8.0, with and without the addition of 10 mM ethylenediaminetetraacetic acid as a metalloelastase inhibitor or 10 mM N-methoxysuccinyl-Ala-Ala-Pro-Val chloromethyl ketone as a serine elastase inhibitor.

BAL samples were assayed in duplicate wells of 96-well flat bottom plates (VWR Canlab, Mississauga, ON, Canada). Each well contained 100 µl of the appropriate assay buffer as described earlier, 50 µl of 0.5 mg/ml SLAPN substrate, and 50 µl of sample. Negative control wells contained 150 µl of assay buffer and 50 µl of substrate. Background absorbance of each BAL sample was assessed by incubating 150 µl of assay buffer with 50 µl of BALF (this value was subtracted from the absorbance of the test wells). The absorbance of the wells was measured at 405 nm wavelength.

Statistics

Most comparisons were made by analysis of variance. Because neutrophil counts were often zero (especially in control animals and the neutrophil depletion or alpha 1AT treatment groups), comparisons were performed with the nonparametric Kruskal-Wallis test, although the graphs show means and standard deviations (SDs). Values of P < 0.05 or less were considered significant.

    Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Figure 1 shows the effects of cigarette dose with death at 24 h after smoke exposure. Lavage PMNs but not MACs increased with number of cigarettes smoked, but with a plateau after two cigarettes. Lavage DES and HP also increased with smoke dose in a similar fashion.


View larger version (16K):
[in this window]
[in a new window]
 
Figure 1.   Lavage PMNs (top left), DES (bottom left), and HP (bottom right) (measured at 24 h) increase with increasing numbers of cigarettes, with a plateau after two cigarettes. Lavage MAC numbers (top right) are not changed. *Significantly greater than control. Values are means ± SD.

Figure 2 shows the effects over time of a single exposure to two cigarettes. PMNs were increased at 6 h, although the difference from control was not statistically significant, and were significantly elevated at 24 h. By 48 h neutrophil counts had decreased. MAC numbers were not affected by smoke. Both lavage DES and HP were increased at 6 and 24 h, but returned to baseline at 48 h.


View larger version (27K):
[in this window]
[in a new window]
 
Figure 2.   Lavage PMNs (top left), DES (bottom left), and HP (bottom right) increase to 24 h after a single exposure to two cigarettes (hatched columns), and then decrease to control values (filled columns). Lavage MAC numbers (top right) are not changed. *Significantly greater than control. Values are means ± SD.

Figure 3 shows the effects of anti-PMN antibody administered before smoke exposure as described in MATERIALS AND METHODS. The antibody reduced lavage PMN levels to zero and prevented smoke-mediated increases in DES and HP, again without affecting MAC numbers.


View larger version (23K):
[in this window]
[in a new window]
 
Figure 3.   Anti-PMN antibody reduces PMN counts to zero (top left) (bar in graph is a place marker) in both control and smoke-exposed animals, and also returns smoke-induced elevations of DES (bottom left) and HP (bottom right) to control values. Lavage MAC numbers are not changed (top right). *Significantly greater than control. Values are means ± SD.

Figure 4 shows the effects of exogenous human alpha 1AT administered as described in MATERIALS AND METHODS on serum alpha 1AT levels and the time course of the serum elevation. Serum levels were increased two to three times over normal C57-BL/6 levels (28) at 24 h and declined to baseline over 7 d. Figure 5 illustrates Western blots of lavage fluid in animals given human alpha 1AT; the human protein is present in the lavage fluid of both smoke- and air-exposed animals. Only a single band at 52 kD was observed and no complexes were identified. Figure 6 shows the effects of exogenous alpha 1AT administration 24 h before smoke exposure: alpha 1AT totally abolished the smoke-mediated increases in PMNs, DES, and HP. MAC numbers were not affected by exogenous alpha 1AT.


View larger version (7K):
[in this window]
[in a new window]
 
Figure 4.   Time course of serum human alpha 1AT level after administration of 20 mg of human alpha 1AT. Values are means ± SD.


View larger version (70K):
[in this window]
[in a new window]
 
Figure 5.   Western blot of lavage fluid at 48 h after alpha 1AT administration (24 h after smoke exposure) using antibody against human alpha 1AT. Human alpha 1AT is present in both control (nonsmoked) animals (top panel: lanes 1-5, no human alpha 1AT; lanes 6-9, 20 mg human alpha 1AT; std indicates pure human alpha 1AT) and smoked animals (bottom panel: lanes 1-4, no human alpha 1AT; lanes 5-8, 20 mg human alpha 1AT; and std indicates pure human alpha 1AT).


View larger version (14K):
[in this window]
[in a new window]
 
Figure 6.   Administration of human alpha 1AT 24 h before smoke exposure abolishes smoke-induced elevations in PMN counts (top left), DES (bottom left), and HP (bottom right). MAC numbers are not affected (top right). *Significantly greater than control. Values are means ± SD.

Figure 7 shows lavage serine and metalloelastase-like activity at 24 h after two cigarettes. Cigarette smoke exposure elevated both serine and metalloelastase activity, and alpha 1AT returned the serine but not the metalloelastase levels to control values.


View larger version (21K):
[in this window]
[in a new window]
 
Figure 7.   Smoke elevates both serine and metalloelastase activity in lavage fluid after alpha 1AT administration. Administration of human alpha 1AT 24 h before smoke exposure reduces serine elastase activity to control values, but does not affect metalloelastase activity. *Significantly greater than control. Values are means ± SD.

    Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

In this paper we have examined the acute effects of cigarette smoke on connective tissue breakdown. The controversies regarding the effector cell(s) and protease(s) leading to emphysema were considered in the opening paragraphs. The quantification of connective tissue breakdown in smoke- exposed humans has been similarly problematic and reports using various methods have given inconsistent results. Most investigators have examined urinary DES, and early studies using radioimmunoassays concluded that there was no detectable difference in urine DES levels between control and alpha 1AT-deficient subjects (29) and no correlation between urine DES and smoking status (30). More recent studies suggest that plasma and BALF elastin-derived peptides are increased in smokers with evidence of chronic obstructive pulmonary disease (COPD) (31, 32), and that the highest levels of urinary DES are present in those individuals with the most rapid decline in pulmonary function (33). Augmentation with alpha 1AT reduces urinary DES levels in individuals with alpha 1AT deficiency (34) and preliminary testing of a synthetic serine elastase inhibitor also indicates it is capable of reducing urinary DES excretion in some patients with COPD (35).

Apart from problems of interfering substances, measurement of urinary or plasma DES is not entirely specific because it will pick up the normal elastin turnover from all organs in the body; Gottlieb and colleagues (33) noted that in normal individuals, only 19% of urinary DES is derived from the lung. Measurements of lavage DES are potentially more informative, but few data are available. Ofulue and associates (24) recently reported that, using a radioimmunoassay, elevated levels of both DES and elastin split products could be detected in the lavage fluid of rats 2 mo after initial smoke exposure, but not before. The present experiments extend this phenomenon more proximally: elevated levels of DES were evident within 6 h of smoke exposure, indicating that smoke can induce connective tissue breakdown as a very early event. The fact that HP levels were also elevated by 6 h serves to reinforce the idea that the proteolytic attack resulting from cigarette smoke exposure degrades a whole spectrum of matrix components, rather than just elastin.

Because smoke increases epithelial permeability it is remotely possible that smoke-induced leakage of normal serum DES and HP might spuriously increase lavage DES and HP. However, we were not able to detect any DES in normal mouse serum with our HPLC technique, with a detection limit determined from spiked samples of 3 pmol/ ml. By contrast, the lavage DES levels in our control animals were 20 to 30 pmol/ml and in the smoke-exposed animals on the order of 70 pmol/ml. Given that a normal mouse serum volume is about 1.5 ml, serum leakage could not account for more than a very small part of the increase in lavage connective tissue breakdown products.

The present experiments suggest that, in this very acute model of smoke-induced injury, neutrophils act as the initial effector cells involved in connective tissue breakdown. In our animals neutrophils constitute, on average, some 1 to 3% of lavage cells in the smoke-exposed mice, values comparable to those seen in human smokers (8). This increase is more significant than might be thought from such small numbers because in absolute terms, exposure to two cigarettes typically increases neutrophils manyfold (see figures). The importance of increased neutrophil numbers is evident from the experiments using antineutrophil antibody; by reducing neutrophil counts essentially to zero, connective tissue breakdown was abolished. Similarly, the efficacy of exogenous alpha 1AT in preventing connective tissue breakdown suggests that a serine protease is involved (but see later discussion), and the effect of alpha 1AT in abolishing the elevated serine elastase activity in the smokers is evident in Figure 7. Although our experiments do not prove that that protease is neutrophil elastase, this is the likely culprit because it is the most potent elastase in the neutrophil armamentarium and accounts for most neutrophil-derived elastolytic activity. However, other neutrophil proteases such as cathepsin G and proteinase 3 may also play a role.

Our experiments raise the possibility that alpha 1AT not only may act to neutralize serine proteases, but also may have an anti-inflammatory effect. DES and HP levels decreased in the animals given human alpha 1AT in these experiments, but neutrophil levels returned to baseline as well, suggesting that alpha 1AT might be preventing connective tissue breakdown by decreasing neutrophil recruitment. Anti-inflammatory effects have been documented for several different antiproteases. Both alpha 1AT and alpha 1-antichymotrypsin have been shown to decrease neutrophil chemotaxis in vitro (36, 37), at least partly by inhibiting the neutrophil-derived protease, cathepsin G, or by interacting with a neutrophil surface-associated chymotrypsin-like enzyme, both of which appear to function in this context to potentiate the chemotactic response (37). Secretory leukocyte protease inhibitor (SLPI) also decreases PMN influx but by a different mechanism: Lentsch and coworkers (38) have proposed that SLPI increases cytoplasmic Ikappa B and prevents activation of nuclear factor-kappa B, leading to decreased endothelial intercellular adhesion molecule-1 expression and decreased egress of PMNs from the circulation into the lung. We are currently investigating the actions of alpha 1AT in this regard.

However, alpha 1AT can also act to upregulate the inflammatory response, inasmuch as complexes of alpha 1AT and neutrophil elastase (39) or alpha 1AT that has been proteolytically inactivated by macrophage elastase (40) act as neutrophil chemoattractants. Moreover, both elastin- and collagen- derived peptides are chemotactic for neutrophils (41, 42), so it is also possible that by inhibiting neutrophil-mediated matrix proteolysis, alpha 1AT prevents formation of chemotactic peptide fragments and thus shuts off a positive feedback cycle. The current data on cigarette smoke exposure do not allow us to distinguish these possibilities. But it is interesting that when we administered alpha 1AT along with LPS to mice, we were able to return lavage DES completely to control values even though lavage PMNs remained markedly elevated at 24 h (R. Dhami, unpublished data), suggesting that direct alpha 1AT-mediated protease neutralization can be important in preventing connective tissue breakdown.

Our data also raise some questions about the exact effects of small differences in alpha 1AT levels. As noted at the beginning of this paper, attempts to show directly that functional levels of alpha 1AT are reduced in smokers have never yielded consistent results. C57-BL/6 mice have alpha 1AT levels that, in human terms, are within the normal range, albeit slightly lower than other standard strains such as NMRI or BALB/c mice (28). Nonetheless, this combination of smoke and endogenous alpha 1AT leads to acute connective tissue breakdown, and the same level of smoke exposure also produces mild emphysema in C57- BL/6 mice if administered daily over 6 mo ([18], and R. Dhami and associates, unpublished data). These findings indicate the protease burden derived from acute cigarette smoke exposure is certainly able to overwhelm the protective effects of endogenous alpha 1AT in C57 mice. It is interesting in this regard that Sandford and colleagues (43) have recently reported the association of cigarette smoke-induced COPD with the alpha 1AT phenotype MZ, where the alpha 1AT levels are about 50% of those seen in MM subjects, but not in MS subjects, where the level is about 75% of MM; and Campbell and coworkers (44) have shown that serum from MZ and MS individuals provides slightly but significantly less proteolytic protection than does serum from MM individuals in an in vitro assay system. The observations not only emphasize the importance of alpha 1AT (and by implication, neutrophil elastase), but also suggest that even fairly small variations in alpha 1AT levels may lead to a situation in which smoke-induced proteolysis overwhelms host defenses.

Our results clearly differ from several recent reports in the literature that emphasize the role of MACs and metalloproteases in smoke-mediated proteolysis, as described in this paper's opening paragraphs. The obvious and crucial difference is that our experiments are very acute and provide no information about long-term changes. We cannot rule out the possibility that MACs, or a combination of neutrophils and MACs (and a combination of serine and metalloproteases), play a greater role over time, as those reports would imply. It is also possible that neutrophil- mediated connective tissue breakdown is entirely a transient process but this seems unlikely since chronic smokers have elevated lavage PMN levels (8); or that compensatory mechanisms serve to neutralize PMN-mediated proteolysis over time, which is one conclusion to be drawn from the data of Ofulue and associates (24) who reported that smoke-induced lavage and interstitial PMNs are increased at 1 mo and then decline in number, whereas MAC increases and increases in lavage DES or elastin split products are not seen until 2 mo. Emphysema, which in that study correlates with lavage DES levels, follows MAC numbers and elastolytic activity. We did not attempt to examine MAC function in the current study and it is possible that MAC protease production is increased; the metalloelastase activity we observed might be due to MAC- or neutrophil-derived enzymes such as gelatinase B  (MMP-9). However, because adminstration of alpha 1AT decreases the serine but not the metalloelastase activity and also returns lavage DES and HP to control levels, metalloproteases do not appear to be playing any acute role in connective tissue breakdown.

It is important to emphasize that the acute production of neutrophil-mediated smoke-induced connective tissue breakdown seen in our model does not necessarily translate into the development of emphysema over time. Unfortunately, the current experiments are necessarily very short-term because repeated administration of anti-PMN antibody or of human alpha 1AT to these animals rapidly leads to the development of serum sickness, making this approach unsuitable for longer studies. However, our data do show that, acutely, smoke-evoked, neutrophil-derived serine proteases can cause connective tissue breakdown in the lung, and that alpha 1AT is protective, perhaps through an anti-inflammatory mechanism.

    Footnotes

Address correspondence to: Andrew Churg, M.D., Dept. of Pathology, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, V6T 2B5 Canada. E-mail: achurg{at}interchange.ubc.ca

(Received in original form May 14, 1999 and in revised form August 19, 1999).

Abbreviations: alpha 1-antitrypsin, alpha 1AT; bronchoalveolar lavage, BAL; BAL fluid, BALF; chronic obstructive pulmonary disease, COPD; desmosine, DES; hydroxyproline, HP; high-performance liquid chromatography, HPLC; macrophage, MAC; matrix metalloproteinase, MMP; polymorphonuclear leukocyte, PMN.

Acknowledgments: This work was supported by the Medical Research Council of Canada and the Bayer Blood Partnership Fund.
    References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Snider, G. L., J. Kleinerman, W. Thurlbeck, and Z. Bengali. 1985. The definition of emphysema. Am. Rev. Respir. Dis. 132: 182-185 [Medline].

2. Senior, R. M., and N. R. Anthonisen. 1998. Chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 157: S139-S147 .

3. Pierce, J. A.. 1997. alpha 1-antitrypsin augmentation therapy. Chest 112: 872-873 [Free Full Text].

4. The Alpha-1-Antitrypsin Deficiency Registry Study Group. 1998. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am. J. Respir. Crit. Care Med. 158: 49-59 [Abstract/Free Full Text].

5. Snider, G. L., E. Lucey, and P. J. Stone. 1994. Pitfalls in antiprotease therapy of emphysema. Am. J. Respir. Crit. Care Med. 150: S131-S137 .

6. Evans, M. D., and W. A. Pryor. 1994. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am. J. Physiol. 266: L593-L611 [Abstract/Free Full Text].

7. Ogushi, R., R. Hubbard, C. Vogelmeier, G. Fells, and R. G. Crystal. 1991. Risk factors for emphysema: cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase. J. Clin. Invest. 87: 1060-1065 .

8. Hunninghake, G., and R. G. Crystal. 1983. Cigarette smoking and lung destruction. Am. Rev. Respir. Dis. 128: 833-838 [Medline].

9. Finkelstein, R., R. Fraser, H. Ghezzo, and M. Cosio. 1995. Alveolar inflammation and its relation to emphysema in smokers. Am. J. Respir. Crit. Care Med. 152: 1666-1672 [Abstract].

10. Ludwig, P., B. Schwartz, J. Hoidal, and D. Niewoehner. 1985. Cigarette smoking causes accumulation of polymorphonuclear leukocytes in alveolar septum. Am. Rev. Respir. Dis. 131: 828-830 [Medline].

11. Janoff, A.. 1985. Elastases and emphysema: current assessment of the protease-antiprotease hypothesis. Am. Rev. Respir. Dis. 132: 417-433 [Medline].

12. Eidelman, D., M. Saetta, H. Ghezzo, N. Wang, J. Hoidal, M. King, and M. Cosio. 1990. Cellularity of the alveolar walls in smokers and its relation to alveolar destruction. Am. Rev. Respir. Dis 141: 1547-1552 [Medline].

13. Senior, R., N. Connolly, J. Cury, H. Welgus, and E. Campbell. 1989. Elastin degradation by human alveolar macrophages. Am. Rev. Respir. Dis. 139: 1251-1256 [Medline].

14. Shapiro, S. D.. 1994. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Am. J. Respir. Crit. Care Med. 150: S160-S164 .

15. Senior, R. M., G. L. Griffin, C. J. Fliszar, S. D. Shapiro, G. I. Goldberg, and H. G. Welgus. 1991. Human 92 and 72-kilodalton type IV collagenases are elastases. J. Biol. Chem. 266: 7870-7875 [Abstract/Free Full Text].

16. Cardoso, W. V., H. S. Sekhon, D. M. Hyde, and W. M. Thurlbeck. 1993. Collagen and elastin in human pulmonary emphysema. Am. Rev. Respir. Dis. 147: 975-981 [Medline].

17. Wright, J. L., and A. Churg. 1995. Smoke-induced emphysema in the guinea pig is associated with morphometric evidence of collagen breakdown and repair. Am. J. Physiol. 268: L17-L20 [Abstract/Free Full Text].

18. Hautamaki, R., D. Kobayashi, R. Senior, and S. Shapiro. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277: 2002-2004 [Abstract/Free Full Text].

19. Sansore, R., R. Abboud, C. Becceril, M. Montano, C. Ramos, B. Vanda, and M. Selman. 1997. Effect of exposure of guinea pigs to cigarette smoke on elastolytic activity of pulmonary macrophages. Chest 112: 214-219 [Abstract/Free Full Text].

20. Finlay, G. A., L. R. O'Driscoll, K. J. Russel, E. M. D'Arcy, J. B. Masterson, M. X. Fitzgerald, and C. M. O'Connor. 1997. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 156: 240-247 [Abstract/Free Full Text].

21. Selman, M., M. Montano, C. Ramos, B. Vanda, C. Becerril, F. Delgado, R. Sanores, R. Barrios, and A. Pardo. 1996. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase. Am. J. Physiol. L734-L739.

22. D'Armiento, J., S. Dalal, Y. Okada, R. Berg, and K. Chada. 1992. Collagenase expression in the lung of transgenic mice causes pulmonary emphysema. Cell 71: 955-961 [Medline].

23. Ohnishi, K., M. Takagi, Y. Kurokawa, S. Satomi, and Y. Konttinen. 1998. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. 78: 1077-1086 [Medline].

24. Ofulue, A., M. Ko, and R. Abboud. 1998. Time course of neutrophil and macrophage elastinolytic activities in cigarette smoke-induced emphysema. Am. J. Physiol. 275: L1134-L1144 [Abstract/Free Full Text].

25. Ofulue, A. F., and M. Ko. 1999. Effects of depletion of neutrophils or macrophages on development of cigarette smoke induced emphysema. Am. J. Physiol. 277: L97-L105 [Abstract/Free Full Text].

26. Sekhon, H., J. L. Wright, and A. Churg. 1994. Cigarette smoke causes rapid cell proliferation in small airways and associated pulmonary arteries. Am. J. Physiol. 267: L557-L563 [Abstract/Free Full Text].

27. Zay, K., S. Loo, C. Xie, D. V. Devine, J. Wright, and A. Churg. 1999. The role of neutrophils and alpha -1-antitrypsin in coal and silica-induced connective tissue breakdown. Am. J. Physiol. 276: L269-L279 [Abstract/Free Full Text].

28. Gardi, C., E. Cavarra, P. Calzoni, P. Maracolongo, M. de Santi, and P. Martorana. 1994. Neutrophil lysosomal dysfunctions in mutant C57-Bl/6J mice: interstrain variations in content of lysosomal elastase, cathepsin G and their inhibitors. Biochem. J. 299: 237-245 .

29. Pelham, F., M. Wewers, R. G. Crystal, A. Buist, and A. Janoff. 1985. Urinary excretion of desmosine in subjects with PiZZ alpha-1-antitrypsin deficiency, a phenotype associated with hereditary predisposition to pulmonary emphysema. Am. Rev. Respir. Dis. 132: 821-823 [Medline].

30. Davies, S., K. Offord, M. Brown, H. Campe, and D. Niewoehner. 1983. Urine desmosine is unrelated to cigarette smoking or to spirometric function. Am. Rev. Respir. Dis. 128: 473-475 [Medline].

31. Schriver, E., J. Davidson, M. Sutcliffe, B. Swindell, and G. Bernard. 1992. Comparison of elastin peptide concentrations in body fluids from healthy volunteers, smokers, and patients with COPD. Am. Rev. Respir. Dis. 245: 762-766 .

32. Stone, P. J., D. Gottlieb, G. O'Connor, D. Ciccolella, R. Breuer, J. Bryan-Rhadfi, H. Shaw, C. Franzbalu, and G. L. Snider. 1995. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 151: 952-959 [Abstract].

33. Gottleib, D., P. J. Stone, D. Sparrow, M. Gale, S. Weiss, G. Snider, and S. O'Connor. 1996. Urinary desmosine excretion in smokers with and without rapid decline of lung function. Am. J. Respir. Crit. Care Med. 154: 1290-1295 [Abstract].

34. Stone, P. J., T. Morris, C. Franzblau, and G. L. Snider. 1995. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin deficient humans. Respiration 62: 76-79 [Medline].

35. Luisetti, M., C. Sturani, D. Sella, E. Madonini, V. Galavotti, G. Bruno, U. Kucich, G. Dagnino, J. Rosenbloom, B. Starcher, and C. Grassi. 1996. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Respir. J. 9: 1482-1486 [Abstract].

36. Stockley, R. A., J. Shaw, S. C. Afford, H. M. Morrison, and D. Burnett. 1990. Effect of alpha -1-proteinase inhibitor on neutrophil chemotaxis. Am. J. Respir. Cell Mol. Biol. 2: 163-170 .

37. Lomas, D. A., S. R. Stone, C. Llewellyn-Jones, M. T. Keogan, Z. M. Wang, H. Rubin, R. W. Carrell, and R. A. Stockley. 1995. The control of neutrophil chemotaxis bv inhibitors of cathepsin G and chymotrypsin. J. Biol. Chem. 270: 23437-23443 [Abstract/Free Full Text].

38. Lentsch, A. B., J. A. Jordan, B. J. Czemak, K. M. Diehl, E. M. Younkin, V. Sarma, and P. Ward. 1999. Inhibition of NF-kappa B activation and augmentation of Ikappa Bbeta by secretory leukocyte protease inhibitor during lung inflammation. Am. J. Pathol. 154: 239-247 [Abstract/Free Full Text].

39. Banda, M. J., A. G. Rice, G. L. Griffin, and R. M. Senior. 1988. alpha 1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. J. Biol. Chem. 263: 4481-4484 [Abstract/Free Full Text].

40. Banda, M. J., A. G. Rice, G. L. Griffin, and R. M. Senior. 1988. The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J. Exp. Med. 167: 1608-1615 [Abstract/Free Full Text].

41. Riley, D. J., R. A. Berg, R. A. Soltys, J. S. Kerr, H. N. Gusds, S. F. Curren, and D. L. Laskin. 1988. Neutrophil response following intratracheal instillation of collagen peptides into rat lungs. Exp. Lung Res. 14: 549-563 [Medline].

42. Senior, R. M., G. L. Griffin, and R. P. Mecham. 1980. Chemotactic activity of elastin-derived peptides. J. Clin. Invest. 66: 859-862 .

43. Sandford, A. J., T. Weir, J. J. Spinelli, and P. D. Pare. 1999. Z and S mutations of the alpha -1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 20: 287-291 [Abstract/Free Full Text].

44. Campbell, E. J., M. A. Campbell, S. S. Boudkedes, and C. A. Owen. 1999. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha(1)-antitrypsin deficiency. J. Clin. Invest. 104: 337-344 [Medline].





This article has been cited by other articles:


Home page
Eur Respir JHome page
K. F. Chung and I. M. Adcock
Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction
Eur. Respir. J., June 1, 2008; 31(6): 1334 - 1356.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Churg, M. Cosio, and J. L. Wright
Mechanisms of cigarette smoke-induced COPD: insights from animal models
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
A. Churg, R. Wang, X. Wang, P.-O. Onnervik, K. Thim, and J. L Wright
Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs
Thorax, August 1, 2007; 62(8): 706 - 713.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
T. S. Nawrot, A. Nemmar, and B. Nemery
Update in Environmental and Occupational Medicine 2006
Am. J. Respir. Crit. Care Med., April 15, 2007; 175(8): 758 - 762.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Janciauskiene, I. M. Nita, and T. Stevens
{alpha}1-Antitrypsin, Old Dog, New Tricks: {alpha}1-ANTITRYPSIN EXERTS IN VITRO ANTI-INFLAMMATORY ACTIVITY IN HUMAN MONOCYTES BY ELEVATING cAMP
J. Biol. Chem., March 23, 2007; 282(12): 8573 - 8582.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Schroeder, M. F. Vidal Melo, G. Musch, R. S. Harris, T. Winkler, and J. G. Venegas
PET Imaging of Regional 18F-FDG Uptake and Lung Function After Cigarette Smoke Inhalation
J. Nucl. Med., March 1, 2007; 48(3): 413 - 419.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Churg, H. Tai, T. Coulthard, R. Wang, and J. L. Wright
Cigarette Smoke Drives Small Airway Remodeling by Induction of Growth Factors in the Airway Wall
Am. J. Respir. Crit. Care Med., December 15, 2006; 174(12): 1327 - 1334.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
E. Kriegova, C. Melle, V. Kolek, B. Hutyrova, F. Mrazek, A. Bleul, R. M. du Bois, F. von Eggeling, and M. Petrek
Protein Profiles of Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1145 - 1154.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
R O'Donnell, D Breen, S Wilson, and R Djukanovic
Inflammatory cells in the airways in COPD
Thorax, May 1, 2006; 61(5): 448 - 454.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
O. Senn, E. W. Russi, M. Imboden, and N. M. Probst-Hensch
{alpha}1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants
Eur. Respir. J., November 1, 2005; 26(5): 909 - 917.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
C. A. Owen
Proteinases and Oxidants as Targets in the Treatment of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 373 - 385.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M.-H. Wu, Y. Shoji, M.-C. Wu, P.-C. Chuang, C.-C. Lin, M.-F. Huang, and S.-J. Tsai
Suppression of Matrix Metalloproteinase-9 by Prostaglandin E2 in Peritoneal Macrophage Is Associated with Severity of Endometriosis
Am. J. Pathol., October 1, 2005; 167(4): 1061 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. H. Thatcher, N. A. McHugh, R. W. Egan, R. W. Chapman, J. A. Hey, C. K. Turner, M. R. Redonnet, K. E. Seweryniak, P. J. Sime, and R. P. Phipps
Role of CXCR2 in cigarette smoke-induced lung inflammation
Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L322 - L328.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. A. Birrell, S. Wong, D. J. Hele, K. McCluskie, E. Hardaker, and M. G. Belvisi
Steroid-resistant Inflammation in a Rat Model of Chronic Obstructive Pulmonary Disease Is Associated with a Lack of Nuclear Factor-{kappa}B Pathway Activation
Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 74 - 84.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
S. Ito, E. P. Ingenito, K. K. Brewer, L. D. Black, H. Parameswaran, K. R. Lutchen, and B. Suki
Mechanics, nonlinearity, and failure strength of lung tissue in a mouse model of emphysema: possible role of collagen remodeling
J Appl Physiol, February 1, 2005; 98(2): 503 - 511.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Churg, R. D. Wang, H. Tai, X. Wang, C. Xie, and J. L. Wright
Tumor Necrosis Factor-{alpha} Drives 70% of Cigarette Smoke-induced Emphysema in the Mouse
Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 492 - 498.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
H van der Vaart, D S Postma, W Timens, and N H T Ten Hacken
Acute effects of cigarette smoke on inflammation and oxidative stress: a review
Thorax, August 1, 2004; 59(8): 713 - 721.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
S. S. Valenca, K. Da Hora, P. Castro, V. G. Moraes, L. Carvalho, and L. Cristo Vao De Moraes Sobrino Porto
Emphysema and Metalloelastase Expression in Mouse Lung Induced by Cigarette Smoke
Toxicol Pathol, April 1, 2004; 32(3): 351 - 356.
[Abstract] [PDF]


Home page
Eur Respir JHome page
E{-}J.D. Oudijk, J{-}W.J. Lammers, and L. Koenderman
Systemic inflammation in chronic obstructive pulmonary disease
Eur. Respir. J., November 2, 2003; 22(46_suppl): 5s - 13s.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
H. Numanami, S. Koyama, D. K. Nelson, J. C. Hoyt, J. L. Freels, M. P. Habib, J. Amano, M. Haniuda, E. Sato, and R. A. Robbins
Serine Protease Inhibitors Modulate Smoke-Induced Chemokine Release From Human Lung Fibroblasts
Am. J. Respir. Cell Mol. Biol., November 1, 2003; 29(5): 613 - 619.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. A. Stockley
"Knock-out" Mouse: Down But Not Out
Am. J. Respir. Crit. Care Med., July 15, 2003; 168(2): 145 - 146.
[Full Text] [PDF]